Tag: evidence-based medicine
-
Lyme Disease Misinformation and Celebrity Influence: Experts Speak
Lyme disease misinformation and the role of celebrities Lyme disease has long been a battleground of medical facts and misinformation. In the online era, a handful of high-profile posts can ripple through social media, shaping how people understand symptoms, diagnosis, and treatment. While celebrities like Bella Hadid bring attention to living with chronic illness, experts…
-
Lyme Disease Misinformation: Celebrity Influence and Expert Guidance
Why Lyme disease misinformation spreads Lyme disease remains a topic of intense interest and debate. While science provides clear answers on diagnosis, treatment, and prevention, a steady stream of misinformation persists online. Misinformation can range from misunderstood symptoms and questionable treatments to grand claims about cures or conspiracies about the medical system. In today’s information…
-
Ivermectin and COVID-19: What the Science Really Says
Understanding the ivermectin conversation during the COVID-19 pandemic As COVID-19 spread across the globe, interest in various treatments grew rapidly. Ivermectin, a long-standing antiparasitic drug, became a focal point of discussion far beyond its approved uses. Proponents cited laboratory studies and early clinical reports, while health authorities urged caution until robust evidence emerged. This tension…
-
Tiger BioSciences Highlights 2025 Clinical Milestones After Bold Research Investment
Overview: A Year of Strategic Investment and Impact In 2025, Tiger BioSciences positioned itself at the forefront of evidence-based biotherapeutics, translating a significant investment in scientific research into tangible clinical milestones. The company’s renewed emphasis on rigorous preclinical validation, translational science, and disciplined trial design aimed to accelerate the journey from discovery to patient impact.…
-
How Social Capital and Evidence-Based Orientation Shape Psychiatrists’ Views on Antipsychotic Polypharmacy in Schizophrenia
Overview: Why Attitudes Toward Antipsychotic Polypharmacy Matter Antipsychotic polypharmacy (APP) — the concomitant use of two or more antipsychotic drugs — remains a contentious issue in schizophrenia management. While some guidelines advise caution and careful monitoring, others acknowledge tailored approaches when monotherapy fails. Understanding what shapes psychiatrists’ attitudes toward APP is essential because clinician preferences…